Ramy Ibrahim, M.D., Parker Institute for Cancer Immunotherapy, explains the combination of Gemcitabine + Abraxane – Standard for Pancreatic Cancer | Investigational Agents – Nivolumab-Anti-PD1 & Anti-CD40.
Gemcitabine + Abraxane – Standard for Pancreatic Cancer | Investigational Agents – Nivolumab-Anti-PD1 & Anti-CD40
By Editor